Raj Makkar

Raj Makkar

Interventional cardiologist / Cardiologist
Cedars-Sinai Medical Center - Los Angeles, United States of America

Latest contributions

Aortic regurgitation in 2026

21 May 2026 – From EuroPCR 2026

Get a comprehensive overview of contemporary management strategies for aortic regurgitation, a condition that remains frequently underdiagnosed and undertreated despite significant advances in transcatheter therapies thanks to this EuroPCR 2026 session.

The programme reviews current diagnostic and treatment pathways, including guideline-based management and the role of surgical...

Aortic regurgitation in 2026

Spotlight - TAVI durability: contemporary evidence and future directions

21 May 2026 – From EuroPCR 2026

Focusing on TAVI durability, this session reviews recent clinical evidence from randomized trials and large registries, examining procedural and device-related factors influencing long-term valve performance. It also discusses challenges in follow-up and implications for future trial designs and device monitoring.

New frontiers: TAVI for aortic regurgitation with conventional and dedicated devices

20 May 2026 – From EuroPCR 2026

This session explores new frontiers in transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation. It addresses the challenges inherent to this indication, reviews treatment approaches using conventional balloon-expandable and self-expandable devices, and presents recent data along with dedicated TAVI devices designed specifically for aortic...

Challenging TAVI access: exploring transfemoral boundaries and mastering alternative access

20 May 2026 – From EuroPCR 2026

This session investigates the boundaries of transfemoral access for TAVI and strategies to safely extend its use. It also provides a comprehensive review of facilitated transfemoral TAVI techniques and explores alternative access options, offering critical insights for managing challenging TAVI cases.

Transcatheter mitral interventions: outcomes and new procedural approaches

20 May 2026 – From EuroPCR 2026

This session covers transcatheter mitral interventions, comparing surgical and transcatheter approaches, including TEER and TMVR. It presents clinical outcomes, safety data, and innovative procedural techniques such as transeptal BATMAN to prevent left ventricular outflow tract obstruction during TMVR.

TAVI aortic regurgitation: LIVE Educational Case from University Medical Centre - Mainz, Germany

20 May 2026 – From EuroPCR 2026

This educational session reviews the management of pure native aortic regurgitation via TAVI, including indications and selection criteria for dedicated transcatheter heart valve devices. It details procedural planning steps such as anatomical assessment, imaging strategies, and device positioning, supplemented by a live case demonstration highlighting key...

How can we improve the management of aortic stenosis in 2026?

19 May 2026 – From EuroPCR 2026

As aortic stenosis management continues to evolve, this EuroPCR 2026 session looks ahead to the challenges and opportunities shaping clinical practice in 2026. From implementing the latest guidelines in daily care to refining the timing of intervention, the discussion focuses on how earlier identification and treatment...

How can we improve the management of aortic stenosis in 2026?

Transcatheter tricuspid valve replacement - LIVE Case

18 Nov 2025 – From PCR London Valves 2025

Live case: An 86-year-old male, with a history of PPM, permanent AF, CKD stage 3, and moderately impaired LV function (50–55%), presented with symptomatic torrential mixed TR (tricuspid annular dilatation and pacing lead on the septal leaflet). An Evoque valve was implanted under fluoroscopy and TEE...

Transcatheter tricuspid valve replacement - LIVE Case

Spotlight on a selection of top Late-breaking Trials presented at PCR London Valves 2025

17 Nov 2025

View a snapshot of the results of these 4 trials in valvular and structural interventions presented in London during this year's Heart Team Course!

Mitral TEER and LAA closure - LIVE Case

17 Nov 2025 – From PCR London Valves 2025

Watch a LIVE case followed by a recorded case regarding a 91-year-old female with permanent AF, LAD PCI three months earlier, and recurrent GID bleeding who presented with symptomatic severe primary mitral regurgitation due to P2 prolapse and flail. CT imaging showed a LAA with a...

Mitral TEER and LAA closure -  LIVE Case

TAVI for pure aortic regurgitation: different animal, different challenges, different approaches

17 Nov 2025 – From PCR London Valves 2025

This session delves into the unique anatomical and pathophysiological challenges posed by pure aortic regurgitation and their impact on treatment strategies. It reviews clinical outcomes with established and new transcatheter devices, and presents emerging technologies that promise to advance therapeutic options for this distinct patient population.

TAVI for pure aortic regurgitation: different animal, different challenges, different approaches

Hot topics in structural heart: addressing patients' unmet needs with EVOQUE TTVR and SAPIEN THV-in-THV

17 Nov 2025 – From PCR London Valves 2025

This session addresses emerging topics in structural heart disease by examining patient-centered solutions such as EVOQUE transcatheter tricuspid valve replacement (TTVR) and SAPIEN transcatheter heart valve-in-heart valve (THV-in-THV) procedures. It covers the latest data from Europe on redo TAVI, lifetime management strategies beginning with initial prosthesis...

Hot topics in structural heart: addressing patients' unmet needs with EVOQUE TTVR and SAPIEN THV-in-THV

TAVI for aortic regurgitation in high surgical risk: outcomes in 700 patients from ALIGN-AR

12 Feb 2026 – From PCR London Valves 2025

Christopher Allen and Raj Makkar sit down to review the ALIGN-AR trial and its implications for treating native aortic regurgitation. 

ALIGN-AR was a pivotal, single-arm, multicenter investigational study designed to evaluate a dedicated transcatheter solution in patients with moderate-to-severe native AR who were considered high risk for...

Outcomes in 700 patients from ALIGN-AR regarding TAVI for AR in high surgical risk

Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1

16 Nov 2025 – From PCR London Valves 2025

This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...

The Top Late-Breaking Trials - Part 1

Hotline - Mitral and tricuspid valvular interventions

16 Nov 2025 – From PCR London Valves 2025

This session delves into innovative mitral and tricuspid valvular interventions, highlighting outcomes with the PASCAL precision system and advances in combined MitraClip and TriClip repairs. It discusses predictors of heart failure hospitalization post-transcatheter tricuspid valve repair (TTVR), coronary CT-based pacemaker implantation prediction, and novel devices aimed...

Updates in transcatheter MVR

21 May 2025 – From EuroPCR 2025

This session provides a detailed overview of recent advances in transcatheter mitral valve replacement (TMVR). Examine outcomes from next-generation transcatheter heart valves, long-term clinical data from mitral valve-in-valve and valve-in-ring procedures, and explore innovative approaches including transseptal MVR with insights from global studies.

Updates in transcatheter MVR

Hotline TAVI 2: outcomes with new and established devices

21 May 2025 – From EuroPCR 2025

Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.

Hotline TAVI 2: outcomes with new and established devices

Transcatheter tricuspid valve replacement in the real world: current data and outcomes

21 May 2025 – From EuroPCR 2025

Explore current real-world data and outcomes of transcatheter tricuspid valve replacement (TTVR). This session reviews UK single-centre experiences, registry data, long-term right ventricular remodeling effects, safety in pacemaker patients, and AI-based CT screening for patient selection.

Transcatheter tricuspid valve replacement in the real world: current data and outcomes

Mitral and tricuspid hotline: long-term outcomes

20 May 2025 – From EuroPCR 2025

Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.

Mitral and tricuspid hotline: long-term outcomes

Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

21 May 2025 – From EuroPCR 2025

Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.

Patients with under-expanded valves faced higher risks...

ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

Clinical and echocardiographic outcomes among the first 500 patients treated with a dedicated transcatheter aortic valve for pure aortic regurgitation in the Align-AR clinical trial

31 Mar 2025

Jonathan Curio interviews Raj Makkar about the results of the Align-AR trial which he presented during the ACC.25 in Chicago.

Jonathan Curio

Author

Jonathan Curio
Raj Makkar

Author

Raj Makkar

TRISCEND II: Top Late Breaking Trial at PCR London Valves 2024

26 Nov 2024 – From PCR London Valves 2024

Chiara De Biase and Raj Makkar share key insights from the TRISCEND II study. This innovative research addresses a crucial question: can transcatheter tricuspid valve replacement improve symptoms, quality of life, and clinical outcomes in patients? Listen as Makkar details the enrolled population and the study's...

TRISCEND II: Top Late Breaking Trial at PCR London Valves 2024

Multivalve disease: defining pathways for optimal assessment and treatment in the absence of good clinical evidence

26 Nov 2024 – From PCR London Valves 2024

Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!

You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...

Multivalve disease: defining pathways for optimal assessment and treatment in the absence of good clinical evidence

TAVI for pure aortic regurgitation - LIVE case

25 Nov 2024 – From PCR London Valves 2024

Watch a LIVE case followed by a recorded case on aortic regurgitation:

  • An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
TAVI for pure aortic regurgitation

TAVI for aortic regurgitation

25 Nov 2024 – From PCR London Valves 2024

Curious about advancing your knowledge in TAVI for aortic regurgitation? Don’t miss this video!

You'll dive into the diagnostic and treatment strategies to optimize outcomes in patients with aortic regurgitation, explore groundbreaking technologies like the Jenavalve Trilogy THV system and gain insights from the latest clinical evidence and...

TAVI for aortic regurgitation

Optimisation of your valve implantation to ensure lifelong outcomes using a novel self-expanding valve

24 Nov 2024 – From PCR London Valves 2024

Gain insights into the importance of valve optimization post-implantation to secure acute and long-term outcomes. In this session, you will discover the new features and benefits of the ACURATE Prime platform illustrated by a recorded case, and compare how different TAVI platforms perform when treating larger...

Optimisation of your valve implantation to ensure lifelong outcomes using a novel self-expanding valve

Insights from the top late-breaking trials at PCR London Valves 2024

24 Nov 2024 – From PCR London Valves 2024

Looking to stay ahead in transcatheter valve therapies? Don't miss out this video showcasing the most impactful late-breaking trials from PCR London Valves 2024.

Discover pivotal findings, including one-year results comparing two balloon-expandable TAVI valves, outcomes of the TRISCEND II trial for tricuspid regurgitation and groundbreaking insights...

Insights from the top late-breaking trials at PCR London Valves 2024

New data on TAVI

16 May 2024 – From EuroPCR 2024

This session presents the latest research and data on transcatheter aortic valve implantation (TAVI). It covers a range of topics, including long-term results of TAVI versus surgical aortic valve replacement in low-risk severe aortic stenosis, real-world experience with novel transcatheter heart valve devices, outcomes in patients...

New data on TAVI

Bicuspid disease - All you need to know

16 May 2024 – From EuroPCR 2024

This session is ideal if you want to understand the anatomical features of bicuspid aortic stenosis, learn about the latest post-TAVI clinical outcomes in bicuspid aortic valves, grasp key considerations for TAVI sizing in these cases, and analyze both self-expanding and balloon-expandable TAVI procedures in bicuspid...

Bicuspid disease - All you need to know

Elevating quality of heart valve treatment through innovation: SAPIEN 3 Ultra RESILIA and EVOQUE valve systems

14 May 2024 – From EuroPCR 2024

Watch this session to explore how the SAPIEN 3 Ultra RESILIA valve can enhance lifetime management for patients, to find out more about the new treatment options available with the EVOQUE valve, identifying the patient populations that stand to benefit the most, and, additionally, to get...

Elevating quality of heart valve treatment through innovation: SAPIEN 3 Ultra RESILIA and EVOQUE valve systems